This indicator reflects a crucial aspect of maternal health by measuring the proportion of women who experienced live births in the two years prior to a survey and who received preventive treatment for malaria through the administration of sulfadoxine-pyrimethamine (SP/Fansidar) in two or more doses during their pregnancy. Such preventive measures are vital for reducing the incidence of malaria-related complications, which can significantly affect both maternal and fetal health. Ensuring that pregnant women have access to effective antimalarial drugs not only improves their health outcomes but also contributes to better overall child survival rates. Monitoring this indicator helps identify gaps in healthcare access and treatment adherence, guiding efforts to enhance maternal and child health services in malaria-endemic regions.
Source: